1. Home
  2. GTN vs TRDA Comparison

GTN vs TRDA Comparison

Compare GTN & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gray Television Inc.

GTN

Gray Television Inc.

HOLD

Current Price

$4.69

Market Cap

452.2M

Sector

Industrials

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.88

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTN
TRDA
Founded
1897
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
452.2M
404.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GTN
TRDA
Price
$4.69
$10.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$7.60
$20.00
AVG Volume (30 Days)
1.3M
242.2K
Earning Date
02-26-2026
03-06-2026
Dividend Yield
6.82%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$3,348,000,000.00
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.37
$21.02
P/E Ratio
$10.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.13
$4.93
52 Week High
$6.31
$13.82

Technical Indicators

Market Signals
Indicator
GTN
TRDA
Relative Strength Index (RSI) 54.48 50.47
Support Level $4.56 $10.48
Resistance Level $4.91 $11.41
Average True Range (ATR) 0.24 0.75
MACD 0.05 -0.07
Stochastic Oscillator 70.67 47.60

Price Performance

Historical Comparison
GTN
TRDA

About GTN Gray Television Inc.

Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: